| Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know |
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-09 17:00:45 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said Chen Schor, President and Chief Executive Officer. |
businesswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per. |
businesswire.com |
2025-04-30 20:47:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo. |
businesswire.com |
2025-04-28 20:30:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Appoints Michael Grissinger to the Board of Directors |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t. |
businesswire.com |
2025-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025. Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per sh. |
businesswire.com |
2025-03-31 21:12:00 |
Czytaj oryginał (ang.) |
| Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: “CAR T Approaches in the Autoimmune Space. |
businesswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024. “In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and. |
businesswire.com |
2025-03-06 18:01:00 |
Czytaj oryginał (ang.) |
| Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti. |
businesswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. Fast Track Designation is a process designed. |
businesswire.com |
2025-02-05 09:10:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025. Two individuals were hired by Adicet in January 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 28,600 shares of Adicet's common stock with an exercise price of $0.89 pe. |
businesswire.com |
2025-01-31 20:06:00 |
Czytaj oryginał (ang.) |
| Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York. Details of the event are as follows: Date: Wednesday, February. |
businesswire.com |
2025-01-29 09:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025. “2024 was a momentous year for Adicet as we amplified our efforts in autoimmune diseases and solid tumors. We dosed our first patients in our clinical trials evaluating our gamma delta 1 chimeric a. |
businesswire.com |
2025-01-08 18:10:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on December 31, 2024. One individual was hired by Adicet in December 2024 and granted new hire non-qualified stock options to purchase 9,000 shares of Adicet's common stock with an exercise price of $0.96 per share, the closing p. |
businesswire.com |
2024-12-31 18:48:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC. “Dosing the first patient in our Phase 1 trial of ADI-270 in metastatic/advanced ccRCC is a significant milestone for Adicet as w. |
businesswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. “We are incredibly pleased to welcome Jul. |
businesswire.com |
2024-12-18 09:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024. One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to purchase 6,000 shares of Adicet's common stock with an exercise price of $1.13 per share, the closing p. |
businesswire.com |
2024-11-29 18:44:00 |
Czytaj oryginał (ang.) |
| Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). “Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from th. |
businesswire.com |
2024-11-18 18:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Convergen. |
businesswire.com |
2024-11-16 11:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio to Participate in Upcoming Investor Conferences |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Truist Securities BioPharma Symposium, November 7, 2024, New York, NY Members of management will be available for 1x1 meetings on. |
businesswire.com |
2024-11-01 09:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024. Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 59,800 shares of Adicet's common stock with an exercise price of $1.28. |
businesswire.com |
2024-10-31 19:31:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024. Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 33,600 shares of Adicet's common stock with an exercise price of $1. |
businesswire.com |
2024-09-30 21:08:00 |
Czytaj oryginał (ang.) |
| Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA. Details of the oral presentation are. |
businesswire.com |
2024-09-30 20:30:00 |
Czytaj oryginał (ang.) |
| Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “The favorable safety profile, cellular kinetics and B cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with ADI-001 clinical exper. |
businesswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. Notably, ADI-001 demonstrated robust tissue trafficking resulting in high levels. |
businesswire.com |
2024-09-19 11:00:00 |
Czytaj oryginał (ang.) |
| UL Solutions Warns of Potentially Hazardous Communications Cable |
NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The communications cable does not comply with the appropriate Safety Standards. Name of Product: CAT 5E 350MHZ CMR MODEL NUMBER W-CAT5E/CCU/1000/W UNSHIELDED TWISTED PAIR 24 AWG/4PAIR/1000FT Remedy: UL Solutions recommends that this product be removed from service. Identification on the Cable: E468535. |
businesswire.com |
2024-08-30 23:13:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 30,600 shares of Adicet's common stock with an exercise price of $1.46 pe. |
businesswire.com |
2024-08-30 21:44:00 |
Czytaj oryginał (ang.) |
| Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag |
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024. |
zacks.com |
2024-07-09 14:56:36 |
Czytaj oryginał (ang.) |
| 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns |
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering. |
investorplace.com |
2024-07-02 21:05:56 |
Czytaj oryginał (ang.) |
| Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70. |
businesswire.com |
2024-06-24 11:00:00 |
Czytaj oryginał (ang.) |
| Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 |
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally. |
investorplace.com |
2024-06-10 23:22:44 |
Czytaj oryginał (ang.) |
| Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. “The FDA's decision to grant ADI-001 Fast Track Designation for lupus nephritis. |
businesswire.com |
2024-06-05 11:00:00 |
Czytaj oryginał (ang.) |
| Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024. Two individuals were hired by Adicet in May 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 44,800 shares of Adicet's common stock with an exercise price of $1.45 per share,. |
businesswire.com |
2024-05-31 21:41:00 |
Czytaj oryginał (ang.) |